Radiation dose escalation for localized prostate cancer: Intensity-modulated radiotherapy versus permanent transperineal brachytherapy

Cancer

Volumn 115, Issue 23, 2009, Pages 5596-5606

  Wong, William W ^a   Vora, Sujay A ^a   Schild, Steven E ^a   Ezzell, Gary A ^a   Andrews, Paul E ^a   Ferrigni, Robert G ^a   Swanson, Scott K ^a  

^a MAYO CLINIC   (United States)

Author keywords

3 Dimensional conformal therapy; Brachytherapy; Intensity modulated radiotherapy; Prostate cancer; Radiation dose escalation

Indexed keywords

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ACUTE TOXICITY; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FECES INCONTINENCE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PERMANENT TRANSPERINEAL BRACHYTHERAPY; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; UROGENITAL TRACT DISEASE;

BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RISK;

EID: 72249113812     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24558     Document Type: Article

References (22)

1. Jemal A,Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985;58:515-528.
3. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001; 50:1021-1031.
4. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64:527-533.
5. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with 3-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491-500.
6. Jani AB, Hand CM, Lujan AE, et al. Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans. Med Dosim. 2004;29:42-48.
7. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105.
8. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233-1239. (Pubitemid 41352111)
9. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990-1996. (Pubitemid 46622106)
10. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974. (Pubitemid 28445094)
11. Brachman DG, Thomas T, Hilbe J, Beyer DC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys. 2000;48:111-117. (Pubitemid 30488220)
12. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of 3-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517-522.
13. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol. 2004;71:29-33. (Pubitemid 38452899)
14. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25-33. (Pubitemid 38010333)
15. Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. Cancer J. 2001; 7:404-412. (Pubitemid 33759005)
16. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol. 2004; 171:1132-1136. (Pubitemid 38327542)
17. Harnden P, Shelley MD, Clements H, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer. 2007;109:13-24. (Pubitemid 46120190)
18. Ash D, Bottomley D, Al-Qaisieh B, Carey B, Gould K, Henry A. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother Oncol. 2007;84:135-139. (Pubitemid 47284527)
19. Crook J, Fleshner N, Roberts C, Pond G. Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol. 2008;179:141-145; discussion 146.
20. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007;109:2239-2247. (Pubitemid 46801553)
21. Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006;24:5298-5304.
22. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250-1261.